- Congratulatory remarks
-
Kim KS
- KMID: 2559456
- J Liver Cancer.
- 2024 Sep;24(2):119-119.
- doi: 10.17998/jlc.2024.09.10
-
- CITED
-
- Close
- SHARE
-
- Close
- Inter-reader agreement for LR-M imaging features: a premise for better imaging-based diagnosis in liver imaging
-
Shin J
- KMID: 2559458
- J Liver Cancer.
- 2024 Sep;24(2):124-125.
- doi: 10.17998/jlc.2024.08.06
-
- CITED
-
- Close
- SHARE
-
- Close
- Practical consensus multi-specialty guidelines on image-guided ablation for hepatocellular carcinoma
-
Lu DS
- KMID: 2559457
- J Liver Cancer.
- 2024 Sep;24(2):120-123.
- doi: 10.17998/jlc.2024.09.11
-
- CITED
-
- Close
- SHARE
-
- Close
- The position of loco-regional therapy in the management of hepatocellular carcinoma with extrahepatic metastases
-
Kim BK
- KMID: 2559460
- J Liver Cancer.
- 2024 Sep;24(2):129-130.
- doi: 10.17998/jlc.2024.08.26
-
- CITED
-
- Close
- SHARE
-
- Close
- Exploring the role of liver resection as a first-line treatment option for multinodular BCLC-A hepatocellular carcinoma
-
Oh JH, Sinn DH
- KMID: 2559459
- J Liver Cancer.
- 2024 Sep;24(2):126-128.
- doi: 10.17998/jlc.2024.08.08
-
- CITED
-
- Close
- SHARE
-
- Close
- Outcomes of liver resection and transarterial chemoembolization in patients with multinodular BCLC-A hepatocellular carcinoma
-
Yang J, Choi WM, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Moon DB, Jung DH, Choi J
- KMID: 2559465
- J Liver Cancer.
- 2024 Sep;24(2):178-191.
- doi: 10.17998/jlc.2024.03.25
Backgrounds/Aims: This study aimed to compare the outcomes of liver resection (LR) and transarterial chemoembolization (TACE) in patients with multinodular hepatocellular carcinoma (HCC) within the Milan criteria who were not... -
- CITED
-
- Close
- SHARE
-
- Close
- Disease modifiers and novel markers in hepatitis B virus-related hepatocellular carcinoma
-
Mak LY
- KMID: 2559462
- J Liver Cancer.
- 2024 Sep;24(2):145-154.
- doi: 10.17998/jlc.2024.08.03
Chronic hepatitis B (CHB) infection is responsible for 40% of the global burden of hepatocellular carcinoma (HCC) with a high case fatality rate. The risk of HCC differs among CHB... -
- CITED
-
- Close
- SHARE
-
- Close
- Local ablation for hepatocellular carcinoma: 2024 expert consensus-based practical recommendation of the Korean Liver Cancer Association
-
Han S, Sung PS, Park SY, Kim JW, Hong HP, Yoon JH, Chung DJ, Kwon JH, Lim S, Kim JH, Shin SK, Kim TH, Lee DH, Choi JY, Research Committee of the Korean Liver Cancer Association
- KMID: 2559461
- J Liver Cancer.
- 2024 Sep;24(2):131-144.
- doi: 10.17998/jlc.2024.08.04
Local ablation for hepatocellular carcinoma (HCC), a non-surgical option that directly targets and destroys tumor cells, has advanced significantly since the 1990s. Therapies with different energy sources, such as radiofrequency... -
- CITED
-
- Close
- SHARE
-
- Close
- Recent update of proton beam therapy for hepatocellular carcinoma: a systematic review and meta-analysis
-
Bae SH, Jang WI, Mortensen HR, Weber B, Kim MS, Høyer M
- KMID: 2559475
- J Liver Cancer.
- 2024 Sep;24(2):286-302.
- doi: 10.17998/jlc.2024.06.26
Backgrounds/Aims: Although access to proton beam therapy (PBT) is limited worldwide, its use for the treatment of hepatocellular carcinoma (HCC) is gradually increasing with the expansion of new facilities. Therefore,... -
- CITED
-
- Close
- SHARE
-
- Close
- Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study
-
Han JW, Sohn W, Choi GH, Jang JW, Seo GH, Kim BH, Choi JY
- KMID: 2559474
- J Liver Cancer.
- 2024 Sep;24(2):274-285.
- doi: 10.17998/jlc.2024.08.13
Backgrounds/Aims: The treatment landscape for hepatocellular carcinoma (HCC) has significantly evolved over the past decade. We aimed to analyze trends in treatment patterns for HCC using a nationwide claims database... -
- CITED
-
- Close
- SHARE
-
- Close
- Downstaging with atezolizumab-bevacizumab: a case series
-
Kulkarni AV, Kumaraswamy P, Menon B, Sekaran A, Rambhatla A, Iyengar S, Alla M, Venishetty S, Ramachandra SK, Premkumar GV, Sharma M, Rao PN, Reddy DN, Singal AG
- KMID: 2559469
- J Liver Cancer.
- 2024 Sep;24(2):224-233.
- doi: 10.17998/jlc.2024.05.12
Backgrounds/Aims: Hepatocellular carcinoma (HCC) is generally diagnosed at an advanced stage, which limits curative treatment options for these patients. Locoregional therapy (LRT) is the standard approach to bridge and downstage... -
- CITED
-
- Close
- SHARE
-
- Close
- Multidisciplinary approaches to downstaging hepatocellular carcinoma: present and future
-
Hwang SY, Choi H, Jeon W, Kim RG
- KMID: 2559464
- J Liver Cancer.
- 2024 Sep;24(2):171-177.
- doi: 10.17998/jlc.2024.08.30
Downstaging of hepatocellular carcinoma (HCC) is typically defined as the reduction in size or number of viable tumors through locoregional therapy (LRT), aiming to meet the established criteria for liver... -
- CITED
-
- Close
- SHARE
-
- Close
- Heavy smoking increases early mortality risk in patients with hepatocellular carcinoma after curative treatment
-
Lee J, Choi JY, Lee SK
- KMID: 2559472
- J Liver Cancer.
- 2024 Sep;24(2):253-262.
- doi: 10.17998/jlc.2024.06.02
Backgrounds/Aims: Although cigarette smoking has been associated with an increased risk of hepatocellular carcinoma (HCC), its association with HCC mortality remains underexplored. We aimed to evaluate the effect of smoking... -
- CITED
-
- Close
- SHARE
-
- Close
- New systemic treatment options for advanced cholangiocarcinoma
-
Zanuso V, Tesini G, Valenzi E, Rimassa L
- KMID: 2559463
- J Liver Cancer.
- 2024 Sep;24(2):155-170.
- doi: 10.17998/jlc.2024.08.07
Cholangiocarcinoma (CCA) is a rare and aggressive cancer, mostly diagnosed at advanced or metastatic stage, at which point systemic treatment represents the only therapeutic option. Chemotherapy has been the backbone... -
- CITED
-
- Close
- SHARE
-
- Close
- Superselective ablative chemo-ethanol embolization for recurrent single hepatocellular carcinoma: a 6-month outcome analysis
-
Lee JH, Kim KY, Lee Ch, Kim M, Yoon CJ
- KMID: 2559468
- J Liver Cancer.
- 2024 Sep;24(2):217-223.
- doi: 10.17998/jlc.2024.05.08
Backgrounds/Aims: To evaluate the safety and effectiveness of superselective ablative chemo-ethanol embolization (SACE) for the treatment of patients with recurrent single hepatocellular carcinoma (rHCC). Methods: This retrospective study included 22 patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Re-assessing the diagnostic value of the enhancing capsule in hepatocellular carcinoma imaging
-
Bae JS, Lee JM, Hur BY, Yoo J, Park SJ
- KMID: 2559467
- J Liver Cancer.
- 2024 Sep;24(2):206-216.
- doi: 10.17998/jlc.2024.05.01
Backgrounds/Aims: The enhancing capsule (EC) in hepatocellular carcinoma (HCC) diagnosis has received varying degrees of recognition across major guidelines. This study aimed to assess the diagnostic utility of EC in... -
- CITED
-
- Close
- SHARE
-
- Close
- Inter-reader agreement for CT/MRI LI-RADS category M imaging features: a systematic review and meta-analysis
-
Kim DH, Choi SH
- KMID: 2559466
- J Liver Cancer.
- 2024 Sep;24(2):192-205.
- doi: 10.17998/jlc.2024.04.05
Backgrounds/Aims: To systematically evaluate inter-reader agreement in the assessment of individual liver imaging reporting and data system (LI-RADS) category M (LR-M) imaging features in computed tomography/magnetic resonance imaging (CT/MRI) LIRADS... -
- CITED
-
- Close
- SHARE
-
- Close
- Cure can be achieved by conversion to microwave ablation following atezolizumab-bevacizumab therapy in unresectable hepatocellular carcinoma
-
Febro RJD, Perillo ESS, Kimura AA, Wong SN
- KMID: 2559470
- J Liver Cancer.
- 2024 Sep;24(2):234-242.
- doi: 10.17998/jlc.2024.05.23
Backgrounds/Aims: Atezolizumab/bevacizumab is the recommended first-line systemic therapy for unresectable hepatocellular carcinoma (uHCC) and may facilitate curative conversion through resection and locoregional therapies. However, there have been very few reports... -
- CITED
-
- Close
- SHARE
-
- Close
- Assessment of real-time US-CT/MR-guided percutaneous gold fiducial marker implementation in malignant hepatic tumors for stereotactic body radiation therapy
-
Hwang S, Chun SJ, Chie EK, Lee JM
- KMID: 2559473
- J Liver Cancer.
- 2024 Sep;24(2):263-273.
- doi: 10.17998/jlc.2024.06.03
Backgrounds/Aims: This study explored the initial institutional experience of using gold fiducial markers for stereotactic body radiotherapy (SBRT) in treating malignant hepatic tumors using real-time ultrasound-computed tomography (CT)/magnetic resonance (MR)... -
- CITED
-
- Close
- SHARE
-
- Close
- Role of transarterial chemoembolization for hepatocellular carcinoma with extrahepatic metastases in the era of advancing systemic therapy
-
Song BG, Goh MJ, Kang W, Sinn DH, Gwak GY, Paik YH, Lee JH, Choi MS
- KMID: 2559471
- J Liver Cancer.
- 2024 Sep;24(2):243-252.
- doi: 10.17998/jlc.2024.05.26
Backgrounds/Aims: Systemic therapy is the current standard treatment for hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM). However, some patients with HCC and EHM undergo transarterial chemoembolization (TACE) to manage intrahepatic... -
- CITED
-
- Close
- SHARE
-
- Close
